Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter, the fund ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences stock tumbled late Tuesday after the company cut its outlook and posted weaker-than-expected results.Shares of ...

Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) gapped down prior to trading on Wednesday after the company ...

Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.

Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday. Puneet Souda’s ...

On Wednesday, Exact Sciences Corp (EXAS) stock saw a decline, ending the day at $54.72 which represents a decrease of $-16.79 or -23.48% from the prior close of $71.51. The stock opened at $55.7 and ...

Exact Sciences (NASDAQ:EXAS – Get Free Report) had its price target boosted by stock analysts at Canaccord Genuity Group from ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Read Next: Trump Media Stock Volatile On Election Eve As Polls, Betting Markets Predict Tight White House Race Outlook: Exact Sciences sees fiscal year 2024 total revenue in a range of $2.73 billion ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tycho ...